financetom
Business
financetom
/
Business
/
Nasdaq Develops AI-Driven Methodology for Investment Portfolio Risk Calculation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nasdaq Develops AI-Driven Methodology for Investment Portfolio Risk Calculation
Oct 17, 2024 2:20 PM

07:05 AM EDT, 10/17/2024 (MT Newswires) -- Nasdaq (NDAQ) said Thursday it has developed an innovative new methodology for investment portfolio risk calculations and predictive analytics, leveraging advanced machine learning capabilities.

The company said the new technology, called the XVA Accelerator, utilizes Chebyshev Tensors, a sophisticated mathematical modeling technique, to enhance the efficiency of complex trading and regulatory risk calculations.

It added that the technology allows financial instruments to be priced across millions of scenarios up to 100 times faster while maintaining high accuracy and reducing the physical infrastructure required for the calculations.

Price: 73.96, Change: +0.20, Percent Change: +0.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge
Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge
May 26, 2025
02:06 PM EDT, 05/16/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Friday a US district court ruled in its favor in formulation patent litigation against Aurobindo Pharma and other abbreviated new drug application filers. The lawsuit involved Acadia's '721 formulation patent for Nuplazid, its treatment for Parkinson's disease psychosis. The US District Court for the District of Delaware...
TIMELINE-From insulin to Ozempic, history of Novo Nordisk's CEOs
TIMELINE-From insulin to Ozempic, history of Novo Nordisk's CEOs
May 26, 2025
May 16 (Reuters) - Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly ( LLY ) . The company has had five CEOs in its more than 100 years of history. Jorgensen, who joined in 2017, has had...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
From insulin to Ozempic, history of Novo Nordisk's CEOs
From insulin to Ozempic, history of Novo Nordisk's CEOs
May 26, 2025
(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly ( LLY ). The company has had five CEOs in its more than 100 years of history. Jorgensen, who joined in 2017, has had the shortest tenure of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved